MicroRNAs as biomarkers for clinical studies
暂无分享,去创建一个
[1] J. Kleinjans,et al. Serum microRNA signatures as "liquid biopsies" for interrogating hepatotoxic mechanisms and liver pathogenesis in human , 2017, PloS one.
[2] Nicholas T. Ingolia,et al. Mammalian microRNAs predominantly act to decrease target mRNA levels , 2010, Nature.
[3] D. Bartel. MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.
[4] A. Warth,et al. Serum miR-142-3p is associated with early relapse in operable lung adenocarcinoma patients. , 2013, Lung cancer.
[5] P. Reddy,et al. Are circulating microRNAs peripheral biomarkers for Alzheimer's disease? , 2016, Biochimica et biophysica acta.
[6] F. Zhan,et al. Low serum miR‐19a expression as a novel poor prognostic indicator in multiple myeloma , 2015, International journal of cancer.
[7] Hongwei Wang,et al. Expression of Serum Exosomal MicroRNA-21 in Human Hepatocellular Carcinoma , 2014, BioMed research international.
[8] I. Pogribny,et al. The role for microRNAs in drug toxicity and in safety assessment , 2015, Expert opinion on drug metabolism & toxicology.
[9] D. Schadendorf,et al. The validity of circulating microRNAs in oncology: Five years of challenges and contradictions , 2014, Molecular oncology.
[10] Mary E Rinella,et al. Nonalcoholic fatty liver disease: a systematic review. , 2015, JAMA.
[11] K. Zen,et al. A Five-miRNA Panel Identified From a Multicentric Case–control Study Serves as a Novel Diagnostic Tool for Ethnically Diverse Non-small-cell Lung Cancer Patients , 2015, EBioMedicine.
[12] A. Harris,et al. Detection of elevated levels of tumour‐associated microRNAs in serum of patients with diffuse large B‐cell lymphoma , 2008, British journal of haematology.
[13] E. Cavarretta,et al. MicroRNAs in Coronary Heart Disease: Ready to Enter the Clinical Arena? , 2016, BioMed research international.
[14] Xiao-jing Yang,et al. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. , 2015, The Lancet. Oncology.
[15] Michael J Kerin,et al. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. , 2010, The oncologist.
[16] X. Chen,et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases , 2008, Cell Research.
[17] L. Henry,et al. Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.
[18] S. Rome,et al. Diagnostic Value of Cell-free Circulating MicroRNAs for Obesity and Type 2 Diabetes: A Meta-analysis. , 2015, Journal of molecular biomarkers & diagnosis.
[19] R. Schnabel,et al. Circulating microRNAs strongly predict cardiovascular death in patients with coronary artery disease—results from the large AtheroGene study , 2016, European heart journal.
[20] C. Croce,et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[21] Ping Shi,et al. Diagnostic value of miR-30d-5p and miR-125b-5p in acute myocardial infarction , 2016, Molecular medicine reports.
[22] Kenneth W Witwer,et al. Circulating microRNA biomarker studies: pitfalls and potential solutions. , 2015, Clinical chemistry.
[23] C. Hammer,et al. Performance of Serum microRNAs -122, -192 and -21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis , 2015, PloS one.
[24] Chien‐Hung Yeh,et al. Clinical significance of microRNAs in chronic and acute human leukemia , 2016, Molecular Cancer.
[25] Y. Toiyama,et al. Serum miR-200c Is a Novel Prognostic and Metastasis-Predictive Biomarker in Patients With Colorectal Cancer , 2014, Annals of surgery.
[26] De-chun Zhang,et al. Serum microRNA-21 as a potential diagnostic biomarker for breast cancer: a systematic review and meta-analysis , 2016, Clinical and Experimental Medicine.
[27] A. Schetter,et al. Identification of a metastasis-specific MicroRNA signature in human colorectal cancer. , 2015, Journal of the National Cancer Institute.
[28] William M. Lee. Drug-induced acute liver failure. , 2013, Clinics in liver disease.
[29] C. Croce,et al. MicroRNAs in Cancer. , 2009, Annual review of medicine.
[30] Aijaz Ahmed,et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. , 2015, Gastroenterology.
[31] H. Brenner,et al. Plasma miR‐122 and miR‐200 family are prognostic markers in colorectal cancer , 2017, International journal of cancer.
[32] W. Jin,et al. Increased Circulating MicroRNA-155 as a Potential Biomarker for Breast Cancer Screening: A Meta-Analysis , 2014, Molecules.
[33] Massimo Negrini,et al. Absolute quantification of cell-free microRNAs in cancer patients , 2015, Oncotarget.
[34] L. Hood,et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury , 2009, Proceedings of the National Academy of Sciences.
[35] Ziyuan Zhao,et al. Dysregulated miR1254 and miR579 for cardiotoxicity in patients treated with bevacizumab in colorectal cancer , 2014, Tumor Biology.
[36] Ke Li,et al. Serum MicroRNA-21 as a Diagnostic Marker for Lung Carcinoma: A Systematic Review and Meta-Analysis , 2014, PloS one.
[37] P. Watkins,et al. The Effects of Heparins on the Liver: Application of Mechanistic Serum Biomarkers in a Randomized Study in Healthy Volunteers , 2012, Clinical pharmacology and therapeutics.
[38] P. Watkins,et al. Benign elevations in serum aminotransferases and biomarkers of hepatotoxicity in healthy volunteers treated with cholestyramine , 2014, BMC Pharmacology and Toxicology.
[39] Andreas Trumpp,et al. Circulating miRNAs with prognostic value in metastatic breast cancer and for early detection of metastasis. , 2016, Carcinogenesis.
[40] M. Mayr,et al. MicroRNAs in Cardiovascular Disease. , 2016, Journal of the American College of Cardiology.
[41] Y. Toiyama,et al. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. , 2013, Journal of the National Cancer Institute.
[42] A. Sanyal,et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis , 2014, Gut.
[43] Q. Lu,et al. The emerging role of circulating microRNAs as biomarkers in autoimmune diseases , 2014, Autoimmunity.
[44] X. Chen,et al. A panel of four decreased serum microRNAs as a novel biomarker for early Parkinson’s disease , 2016, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.
[45] Jonathan Moggs,et al. Circulating microRNAs as potential markers of human drug‐induced liver injury , 2011, Hepatology.
[46] Alasdair J Gray,et al. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital , 2013, Hepatology.
[47] Xianyin Lai,et al. A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer , 2017, Cancer letters.
[48] V. Ambros,et al. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 , 1993, Cell.
[49] S. Szeinbach,et al. Market withdrawal of new molecular entities approved in the United States from 1980 to 2009 , 2011, Pharmacoepidemiology and drug safety.
[50] Y. Devaux,et al. Diagnostic and prognostic value of circulating microRNAs in patients with acute chest pain , 2015, Journal of internal medicine.
[51] Q. Pan,et al. Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population , 2016, World journal of gastroenterology.
[52] Paola Tiberio,et al. Challenges in Using Circulating miRNAs as Cancer Biomarkers , 2015, BioMed research international.
[53] Klaus Pantel,et al. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. , 2016, Cancer discovery.
[54] Y. Devaux,et al. A Panel of 4 microRNAs Facilitates the Prediction of Left Ventricular Contractility after Acute Myocardial Infarction , 2013, PloS one.
[55] P. Dargan,et al. Comprehensive microRNA profiling in acetaminophen toxicity identifies novel circulating biomarkers for human liver and kidney injury , 2015, Scientific Reports.
[56] D. Kriebel,et al. The increasing toll of adolescent cancer incidence in the US , 2017, PloS one.
[57] F. Mancarella,et al. Circulating microRNAs and diabetes mellitus: a novel tool for disease prediction, diagnosis, and staging? , 2017, Journal of Endocrinological Investigation.
[58] William Pao,et al. AACR Cancer Progress Report 2016 , 2016, Clinical Cancer Research.
[59] Daniel B. Martin,et al. Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.
[60] G. Goodall,et al. Circulating microRNAs predict biochemical recurrence in prostate cancer patients , 2013, British Journal of Cancer.
[61] Z. Massy,et al. Serum microRNAs are altered in various stages of chronic kidney disease: a preliminary study , 2016, Clinical kidney journal.
[62] X. Yao,et al. Serum miRNA‐21: Elevated levels in patients with metastatic hormone‐refractory prostate cancer and potential predictive factor for the efficacy of docetaxel‐based chemotherapy , 2011, The Prostate.
[63] J. Bauersachs,et al. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. , 2011, Journal of molecular and cellular cardiology.
[64] L. Räber,et al. Profiling and validation of circulating microRNAs for cardiovascular events in patients presenting with ST-segment elevation myocardial infarction , 2016, European heart journal.
[65] Yuling Hong,et al. Heart Disease and Cancer Deaths — Trends and Projections in the United States, 1969–2020 , 2016, Preventing chronic disease.
[66] Wang He,et al. Diagnostic value of circulating miR-21: An update meta-analysis in various cancers and validation in endometrial cancer , 2016, Oncotarget.
[67] S. Gordon,et al. Circulating microRNAs as Potential Biomarkers of Infectious Disease , 2017, Front. Immunol..
[68] Jiri Aubrecht,et al. Development of Blood Biomarkers for Drug-Induced Liver Injury: An Evaluation of Their Potential for Risk Assessment and Diagnostics , 2013, Molecular Diagnosis & Therapy.
[69] H. Jäck,et al. Serum microRNAs as powerful cancer biomarkers. , 2010, Biochimica et biophysica acta.
[70] M. Denti,et al. Circulating miRNAs as Biomarkers for Neurodegenerative Disorders , 2014, Molecules.
[71] Yongzhi Yang,et al. Systematic literature review and clinical validation of circulating microRNAs as diagnostic biomarkers for colorectal cancer , 2017, Oncotarget.
[72] P. Doevendans,et al. Circulating MicroRNAs as Novel Biomarkers for the Early Diagnosis of Acute Coronary Syndrome , 2013, Journal of Cardiovascular Translational Research.
[73] Jenna Khan,et al. Variability in, variability out: best practice recommendations to standardize pre-analytical variables in the detection of circulating and tissue microRNAs , 2017, Clinical chemistry and laboratory medicine.
[74] H. Baba,et al. Clinical impact of serum exosomal microRNA‐21 as a clinical biomarker in human esophageal squamous cell carcinoma , 2013, Cancer.
[75] D. Fliser,et al. Circulating miR-210 predicts survival in critically ill patients with acute kidney injury. , 2011, Clinical journal of the American Society of Nephrology : CJASN.
[76] A. Mebazaa,et al. Circulating microRNAs and Outcome in Patients with Acute Heart Failure , 2015, PloS one.
[77] A. Laucevičius,et al. Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review , 2016, Cardiovascular research.
[78] Victor R. Ambros,et al. Circulating microRNA profiles in human patients with acetaminophen hepatotoxicity or ischemic hepatitis , 2014, Proceedings of the National Academy of Sciences.